[Clinical studies on flomoxef in respiratory infection]

Clinical efficacy, bacteriological effect and safety of a new antibiotic flomoxef (FMOX, 6315-S) in respiratory infections were studied. Efficacy of FMOX in 6 patients with infectious diseases including 2 cases with pneumonia, 3 cases with acute exacerbation by respiratory infection, 1 case with obstructive pneumonia were clinically evaluated. Two strains of Haemophilus influenzae, 1 strain of Streptococcus pneumoniae and 1 strain of Staphylococcus aureus which were detected as causative organisms in 2 cases disappeared or decreased after treatment with FMOX. Assessing both clinical and bacteriological findings, effects of FMOX were good in 5 cases and fair in 1 case. No adverse effects were observed in clinical or laboratory findings. Consequently, FMOX is considered to be a very useful antibiotic in the treatment for respiratory infectious diseases.